AnaptysBio Management
Management criteria checks 3/4
AnaptysBio's CEO is Dan Faga, appointed in Mar 2022, has a tenure of 2.83 years. total yearly compensation is $7.46M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 1.43% of the company’s shares, worth $7.37M. The average tenure of the management team and the board of directors is 2.8 years and 3.9 years respectively.
Key information
Dan Faga
Chief executive officer
US$7.5m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 2.8yrs |
| CEO ownership | 1.4% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout
Dec 18AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
Nov 21AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet
Nov 07
AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs
Nov 01AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
Aug 15AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)
Jul 08News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 22Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
May 12Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 24Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial
Oct 05Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Sep 14AnaptysBio sells royalties from GSK-partnered Zejula for $45M
Sep 12AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%
Aug 31AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M
Aug 08Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates
May 10Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$166m |
| Jun 30 2024 | n/a | n/a | -US$170m |
| Mar 31 2024 | n/a | n/a | -US$163m |
| Dec 31 2023 | US$7m | US$641k | -US$164m |
| Sep 30 2023 | n/a | n/a | -US$148m |
| Jun 30 2023 | n/a | n/a | -US$144m |
| Mar 31 2023 | n/a | n/a | -US$137m |
| Dec 31 2022 | US$25m | US$474k | -US$129m |
| Sep 30 2022 | n/a | n/a | -US$135m |
| Jun 30 2022 | n/a | n/a | -US$108m |
| Mar 31 2022 | n/a | n/a | -US$76m |
| Dec 31 2021 | US$310k | n/a | -US$58m |
Compensation vs Market: Dan's total compensation ($USD7.46M) is above average for companies of similar size in the US market ($USD2.22M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Faga (44 yo)
2.8yrs
Tenure
US$7,461,920
Compensation
Mr. Daniel R. Faga, also known as Dan, is President, CEO & Director of AnaptysBio, Inc. from August 2023. He was Interim President & CEO and Director of AnaptysBio, Inc. from March 21, 2022 to August 2023....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.8yrs | US$7.46m | 1.43% $ 7.4m | |
| Chief Legal Officer | 6.4yrs | US$2.26m | 0.036% $ 185.7k | |
| Chief Medical Officer | 4.5yrs | US$2.44m | 0.084% $ 432.8k | |
| Chief Financial Officer | 4.5yrs | US$1.81m | 0.045% $ 233.0k | |
| Senior Vice President of Human Resources | 5.3yrs | no data | no data | |
| Senior Vice President of Research | 3yrs | no data | no data | |
| Chief Business Officer | 1yr | no data | no data | |
| Senior Vice President of CMC | 2yrs | no data | no data | |
| Senior Vice President of Corporate Affairs | 1yr | no data | no data | |
| Senior Vice President of Clinical Operations | 1yr | no data | no data | |
| Senior Vice President of Clinical Development | 1yr | no data | no data |
2.8yrs
Average Tenure
55yo
Average Age
Experienced Management: ANAB's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.2yrs | US$7.46m | 1.43% $ 7.4m | |
| Independent Chairman of the Board | 1.3yrs | US$338.08k | 0.011% $ 56.3k | |
| Lead Independent Director | 9.6yrs | US$342.38k | 0.0064% $ 32.9k | |
| Independent Director | 9.6yrs | US$335.38k | 0.15% $ 780.5k | |
| Independent Director | 6.8yrs | US$331.88k | 0.0064% $ 32.9k | |
| Independent Director | 4yrs | US$318.38k | 0.013% $ 65.8k | |
| Independent Director | 3.8yrs | no data | no data | |
| Independent Director | 7.4yrs | US$338.38k | 0.025% $ 126.6k | |
| Independent Director | 1.8yrs | US$495.60k | 0.015% $ 76.5k | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.9yrs
Average Tenure
61yo
Average Age
Experienced Board: ANAB's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 00:18 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AnaptysBio, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Eliana Merle | Cantor Fitzgerald & Co. |
| Alethia Young | Credit Suisse |